OncoMatch/Clinical Trials/NCT06724926
Concurrent Azeliragon With Craniospinal Irradiation
Is NCT06724926 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Azeliragon for solid tumor.
Treatment: Azeliragon — Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Glioblastoma
Disease stage
Metastatic disease required
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9/L, platelet count ≥ 75,000/mm3 (75 × 10^9/L), and hemoglobin (Hgb) ≥ 8 g/dL. Transfusion or growth factor support is allowed.
Kidney function
estimated creatinine clearance of > 30 mL/min (per Cockroft-Gault formula)
Liver function
AST/ALT ≤ 2.5 × ULN, unless liver metastases are present, then ≤ 5 × ULN is acceptable; total bilirubin ≤ 1.5 × ULN
Patients with ANC ≥ 1.0 × 10^9/L, platelet count ≥ 75,000/mm3 (75 × 10^9/L), and hemoglobin (Hgb) ≥ 8 g/dL. Transfusion or growth factor support is allowed. AST/ALT ≤ 2.5 × ULN, unless liver metastases are present, then ≤ 5 × ULN is acceptable, total bilirubin ≤ 1.5 × ULN, and estimated creatinine clearance of > 30 mL/min (per Cockroft-Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Langone Health · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify